1007877-79-3 Usage
Uses
Used in Pharmaceutical Synthesis:
(R)-2-morpholino-2-phenylacetic acid is used as a chiral building block for the development of pharmaceuticals, particularly those targeting central nervous system disorders and psychiatric conditions. Its importance lies in its ability to contribute to the stereoselective synthesis of drugs, ensuring the desired biological activity and efficacy.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-MPA serves as a valuable intermediate due to its unique structure and properties. It facilitates the creation of various biologically active compounds, further expanding its utility in the development of novel pharmaceuticals and other applications.
Used in Drug Development:
The stereochemistry of (R)-2-morpholino-2-phenylacetic acid is essential in drug development, as it allows for the production of drugs with precise biological activities. (R)-2-morpholino-2-phenylacetic acid plays a significant role in the design and synthesis of new medications, especially those aimed at treating central nervous system disorders and psychiatric conditions, where the stereochemistry of the compound can greatly influence the drug's effectiveness and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 1007877-79-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,7,8,7 and 7 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1007877-79:
(9*1)+(8*0)+(7*0)+(6*7)+(5*8)+(4*7)+(3*7)+(2*7)+(1*9)=163
163 % 10 = 3
So 1007877-79-3 is a valid CAS Registry Number.
1007877-79-3Relevant academic research and scientific papers
ANTI-VIRAL COMPOUNDS
-
Paragraph 0308, (2015/11/24)
Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives
Belema, Makonen,Nguyen, Van N.,St. Laurent, Denis R.,Lopez, Omar D.,Qiu, Yuping,Good, Andrew C.,Nower, Peter T.,Valera, Lourdes,O'Boyle II, Donald R.,Sun, Jin-Hua,Liu, Mengping,Fridell, Robert A.,Lemm, Julie A.,Gao, Min,Knipe, Jay O.,Meanwell, Nicholas A.,Snyder, Lawrence B.
, p. 4428 - 4435 (2013/07/26)
The isoquinolinamide series of HCV NS5A inhibitors exemplified by compounds 2b and 2c provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene 2a. Structure-activity relationship (SAR) studies that uncovered an alternate phenylglycine-based cap series that exhibit further improvements in virology profile, along with some insights into the pharmacophoric elements associated with the GT-1a potency, are described.
Anti-Viral Compounds
-
, (2010/11/03)
Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
